Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1426 AL 1440

Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity

Perneczky R, Ghosh BC, Hughes L, Carpenter RH, Barker RA, Rowe JB.

Neurobiol Dis. 2011 Jul;43(1):79-85. doi: 10.1016/j.nbd.2011.01.032. Epub 2011 Feb 17.

Drosophila models of Parkinson's disease

Whitworth AJ.

Adv Genet. 2011;73:1-50. doi: 10.1016/B978-0-12-380860-8.00001-X.

The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy

De Cock VC, Debs R, Oudiette D, Leu S, Radji F, Tiberge M, Yu H, Bayard S, Roze E, Vidailhet M, Dauvilliers Y, Rascol O, Arnulf I.

Brain. 2011 Mar;134(Pt 3):856-62. doi: 10.1093/brain/awq379. Epub 2011 Feb 10.

Flavonoids and the CNS

Jäger AK, Saaby L.

Molecules. 2011 Feb 10;16(2):1471-85. doi: 10.3390/molecules16021471.

Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE.

Mov Disord. 2011 Feb 15;26(3):484-92. doi: 10.1002/mds.23528. Epub 2011 Feb 10.

New non-oral drug delivery systems for Parkinson's disease treatment

Md S, Haque S, Sahni JK, Baboota S, Ali J.

Expert Opin Drug Deliv. 2011 Mar;8(3):359-74. doi: 10.1517/17425247.2011.556616. Epub 2011 Feb 12.

Evaluation of the falls telephone: an automated system for enduring assessment of falls

van der Marck MA, Overeem S, Klok PC, Bloem BR, Munneke M.

J Am Geriatr Soc. 2011 Feb;59(2):340-4. doi: 10.1111/j.1532-5415.2010.03263.x.

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K.

Lancet Neurol. 2011 Mar;10(3):221-9. doi: 10.1016/S1474-4422(11)70012-6.

Rewiring the brain with cell transplantation in Parkinson's disease

Gaillard A, Jaber M.

Trends Neurosci. 2011 Mar;34(3):124-33. doi: 10.1016/j.tins.2011.01.003.

Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation

Fong CY, Rolfs A, Schwarzbraun T, Klein C, O'Callaghan FJ.

Eur J Paediatr Neurol. 2011 May;15(3):271-5. doi: 10.1016/j.ejpn.2011.01.001. Epub 2011 Feb 12.

The deep brain stimulation of the pedunculopontine tegmental nucleus: towards a new stereotactic neurosurgery

Mazzone P, Sposato S, Insola A, Scarnati E.

J Neural Transm (Vienna). 2011 Oct;118(10):1431-51. doi: 10.1007/s00702-011-0593-x. Epub 2011 Feb 12.

The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review

Leentjens AF.

Drugs. 2011 Feb 12;71(3):273-86. doi: 10.2165/11585380-000000000-00000.

Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease

Choi JM, Hong JH, Chae MJ, Ngyuen PH, Kang HS, Ma HI, Kim YJ.

Neurosci Lett. 2011 Apr 15;493(3):97-101. doi: 10.1016/j.neulet.2011.02.013. Epub 2011 Feb 12.

Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study)

Moreno-López C, Santamaría J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser T, Tolosa E.

Arch Neurol. 2011 Feb;68(2):223-30. doi: 10.1001/archneurol.2010.359.

Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease

Benninger DH, Berman BD, Houdayer E, Pal N, Luckenbaugh DA, Schneider L, Miranda S, Hallett M.

Neurology. 2011 Feb 15;76(7):601-9. doi: 10.1212/WNL.0b013e31820ce6bb.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias